Fig. 6: In vivo therapeutic impetus of HGF to PD-L1 checkpoint inhibitor therapy. | Nature Communications

Fig. 6: In vivo therapeutic impetus of HGF to PD-L1 checkpoint inhibitor therapy.

From: A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis

Fig. 6

a Schematic illustration of the experiment design to assess the tumor inhibition and the immune responses as triggered by PBS, anti-PD-L1, HGF or HGF + anti-PD-L1 on subcutaneous B16F10 tumor model. G1, PBS; G2, anti-PD-L1; G3, HGF; G4, HGF + anti-PD-L1. b and c Tumor growth curves during treatment. d Survival rates of different groups over time. e–g Flow cytometric plots and quantification of e CD8+ and f CD3+ g T cells, among CD3+ T cells in the TDLN. h–m Flow cytometric quantification of GzmB+ cells (h–i), Ki67+ cells (j and k) and Tim3+ cells (l and m) in CD8+ and CD4+ T cells. Data were presented as mean ± SD. n = 5 biologically independent animals per group. Statistically significant differences between groups were identified by one-way ANOVA with Tukey’s post hoc test. *P< 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Back to article page